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ABSTRACT 
Background & Aims: Although swallowed topical corticosteroids (STCs) are effective in 
inducing remission of active eosinophilic esophagitis (EoE), there are few data on 
maintenance of long-term remission. We evaluated the long-term effectiveness of STC 
therapy for adults with EoE. 
Methods: We performed a retrospective study using the Swiss EoE database. We analyzed 
data on 229 patients with EoE treated with STCs (175 male; mean age at diagnosis, 39±15 
years; median time until diagnosis, 6 years) from 2000 through 2014. Patients were followed 
for a median 5 years (interquartile range [IQR], 3–7 years). We collected data from 819 
follow-up visits on clinical, endoscopic and histological disease characteristics. The primary 
endpoint was proportions of clinical, endoscopic, and histological remission in all patients 
and groups, based on the status and duration of STC treatment. 
Results: Patients were taking STCs at 336 of the follow-up visits (41.0% of visits). The median 
duration of STC use before a follow-up visit was 347 days (IQR, 90–750 days) corresponding 
to 677 doses (IQR, 280–1413 doses) of 0.25 mg each. At the visits, higher proportions of 
patients who were still taking STCs were in clinical remission (31.0%) compared to patients 
not taking STCs (4.5%) (P<.001), as well as endoscopic remission (48.8% vs 17.8%; P<.001), 
histologic remission (44.8% vs 10.1%; P<.001), and complete remission (16.1% vs 1.3%; 
P<.001). Higher cumulative doses of STCs and longer durations of treatment were associated 
with higher proportions of clinical and complete remission. No dysplasia or mucosal atrophy 
was detected. Esophageal candidiasis was observed at 2.7% of visits in patients taking STCs. 
Conclusion: In an analysis of data from the Swiss EoE database, we found maintenance 
therapy with STCs to achieve complete remission at 16.1% of follow-up visits, which was 
higher than in patients receiving no treatment (1.3%). Given the good safety profile of low-
dose STC, we advocate for a prolonged treatment. Dose-finding trials are needed to achieve 
higher remission rates. 
 
KEY WORDS: esophagus; long-term outcome; predictive factors; response to therapy 
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INTRODUCTION 
 Short-term treatment with swallowed topical corticosteroids (STC) has proven 
efficacy in inducing clinical, endoscopic, and histological remission in adult patients with 
eosinophilic esophagitis (EoE) and has been recently approved by the European Medicines 
Agency.
1-3
 In contrast, data on long-term maintenance treatment are sparse. To date, one 
randomized-controlled trial that included 28 adult patients has been conducted evaluating 
1-year remission rates only.
4 
 Beyond the time frame of one year, the impact of STC treatment on disease course in 
adults with EoE has not been rigorously studied. In the observational study by Kuchen et al. 
long-term use of STC was associated with a reduced risk of long-lasting food impactions.
5
 
Using data from the same population, our group has shown that deep remission, which we 
defined as clinical, endoscopic, and histological remission for at least 6 months, was 
achieved by 9% of the patients.
6
 Almost all of these patients experienced symptomatic 
relapse after discontinuation of STC. Over 90% needed long-term therapeutic management 
and displayed some degree of disease activity when treated with a low dose of 0.5mg STC 
per day.
6
 Nevertheless, we showed that patients benefit from ongoing STC treatment with 
slightly increasing deep remission rates and a reduced risk of long-lasting food impactions 
over time.
5,6
 In spite of these recent findings, the general course of EoE under long-term STC 
management has not been well explored and a comprehensive picture of STC maintenance 
treatment is still missing. It has yet to be determined whether patients clearly benefit from a 
long-term treatment with regards to the rates of clinical, endoscopic, and histological 
remission. 
 Potential side-effects of corticosteroids are a matter of concern for patients 
undergoing long-term treatment. Short-term STC trials have shown that Candida albicans 
infections occur with a frequency of up to 22%, but the risk of infections associated with 
lower maintenance doses has not been rigorously assessed.
1,2,4,6
 In addition, it is well 
established that topical application of corticosteroids to the skin results in epithelial atrophy 
and disruption of epithelial integrity.
7,8
 Since the skin and the esophagus share many 
similarities regarding their histo-morphological structure, this potential side-effect requires 
careful exploration. The data on safety of STC use in 33 patients analyzed in our previous 
study are of some value, but larger studies are needed to assess these safety concerns.
6
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 The purposes of this study were elucidation of the effectiveness as well as 
assessment of the safety profile of long-term use of STC in adult EoE patients. 
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METHODS 
Study design 
In this single-center observational study, we retrospectively evaluated a cohort of EoE 
patients, who received an induction treatment with STC 1.0mg b.i.d. (2-4 weeks until clinical 
response), followed by an infinite maintenance treatment of 0.25mg b.i.d. according to our 
previously published therapeutic concept (Supplementary Methods).
6
 This concept has 
been rigorously applied to all our patients since 2007. Disease activity was assessed 
clinically, endoscopically and histologically on annual basis regardless of presence or absence 
of EoE symptoms. All patients were seen by a single EoE expert (AS). Patients had provided 
written informed consent prior to inclusion into the Swiss EoE database (SEED). The study 
was approved by the local ethics committee (EKNZ 2015-388).  
Patients and data collection 
Set up in 1989, SEED is a nation-wide database of patients with confirmed EoE diagnosis 
established in accordance with defined criteria.
9
 At the time of study analysis, the SEED 
contained data on 783 EoE patients. Inclusion criteria for the SEED have been published 
elsewhere.
6
 For the purpose of this study, the following inclusion criteria were applied: i) 
patients underwent baseline examination and ≥ 1 follow-up examinations (≥ 1 year) with 
standardized assessment of symptoms, endoscopic, and histological findings; ii) patients 
showed clinical response to STC induction treatment within 2-4 weeks; iii) patients were 
treated with a maintenance regimen (0.25mg b.i.d.) after induction of clinical response; and 
iv) the documentation related to the effectiveness of this treatment regimen was available. 
Patients, who followed food elimination diet were excluded from analysis. All documents 
were reviewed and data were extracted from patients’ records by one physician (TG) under 
the close supervision of EoE experts (AS, AMS). Endoscopic disease activity was graded using 
a EoE Endoscopic Reference Score (EREFS) grading and classification system based on the 
available endoscopic pictures.
10
 This EREFS-based score ranges from zero to eight by 
assigning the values of 1 and 2 to mild and severe exudates; 1, 2 and 3 to mild, moderate 
and severe rings; 1 to edema; 1 to furrows; and 1 to strictures. Absence of these features 
was scored with 0. For endoscopic pictures taken before 2012, images were re-assessed in 
retrospect to assign an EREFS score. 
Definitions used in this study 
For the purpose of this study, the following definitions were used: 
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-
 Clinical remission: Absence of any EoE-attributed symptoms,
9
 in particular dysphagia, 
retrosternal pain and heart burn, in patients with unrestricted nutritional habits;
 
- Endoscopic remission: No endoscopic signs of inflammation detectable, in particular 
white exudates, furrows and edema,
10
 mild rings may be present; 
- Histological remission: Peak eosinophil count < 15 eos/ hpf; 
- Complete remission: Combination of clinical, endoscopic, and histological remission. 
- Number of days under STC: consecutive days of STC treatment at the time of follow-up 
visit 
- Cumulative doses of STC: multiples of 0.25mg STC that were cumulatively taken until the 
time of follow-up visit 
Study Endpoints 
As primary endpoint, we determined the proportions of clinical, endoscopic, and histological 
remission in all patients and in patient groups stratified based on the status and duration of 
STC treatment. As secondary endpoints, we examined: i) factors associated with attainment 
of remission, ii) factors associated with presence of symptoms despite endoscopic and 
histological remission, iii) the relationship between clinical, endoscopic, histological, and 
laboratory findings, and iv) STC side-effects. 
Statistical Analysis 
For all statistical analyses, IBM SPSS software (version 22.0.0, 2013 SPSS Science, Chicago, IL) 
was used. Briefly, categorical data was compared using χ
2 
test; differences in quantitative 
data distributions were assessed using the unpaired Student’s t-test and the Mann-Whitney-
Wilcoxon test; multivariate logistic regression was performed by taking into account all 
covariates with a univariate p-value of < 0.1 (Supplementary Methods). For the purpose of 
this study, a p-value of < 0.05 was considered statistically significant. 
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RESULTS 
Patient and disease characteristics at baseline and follow-up visits 
Of a total of 783 eligible patients enrolled in the Swiss EoE database, 229 were included in 
this analysis (175 males, mean age at diagnosis 39±15 years, median diagnostic delay 6 years 
[IQR 2-13], Table 1). Figure 1 depicts the flow-chart for patients` selection in this study as 
well as missing data. In total, 819 follow-up visits (median of 3 visits [IQR 2-5], median 
follow-up time of 5 years [IQR 3-7]) were analyzed (Table 1). Median time between follow-
up visits was 11 months (IQR 3-20). 
Remission during follow-up visits 
The remission proportions for all visits are shown in Figure 2. At the time of the 62 follow-up 
visits, when patients were in complete remission (1.2 years [IQR 0.5-3.7] after enrolment), 
higher use of STC (90.0% of visits vs. 37.9% of visits, p<0.001), longer duration of STC 
treatment (403 [IQR 98-695] vs. 0 days [IQR 0-192], p<0.001), and higher number of STC 
doses of 0.25mg (863 [IQR 361-1301] vs. 0 [IQR 0-430], p<0.001) were observed compared 
to the 757 visits, when patients were not in such remission (1.9 years [IQR 0.7-4.4] after 
enrolment). No differences with regards to the age at disease onset, diagnostic delay, 
gender or atopic history of patients were seen when visits in complete remission were 
compared with visits without such remission. Treatment with STC and a negative family 
history of EoE were independent positive predictors for presence of complete remission at 
the time of follow-up (OR 16.98 [6.69-43.09] and OR 4.02 [1.41-11.47], Table 2).  
Treatment with swallowed topical corticosteroids 
During 336/819 visits (41.0%, 2.1 years [IQR 0.8-4.5] after enrolment), patients were 
undergoing treatment with STC, while during 468 visits (57.1%, 1.7 years [IQR 0.7-4.1] after 
enrolment), patients were without any treatment. For 15 visits, intake of STC could not be 
clearly verified (1.8%). When we compared visits with STC treatment and those without STC, 
no differences with regards to gender and disease characteristics, such as age at diagnosis, 
disease onset, and diagnostic delay, were observed. At visits under STC treatment, median 
peak eosinophil counts (5 vs. 40/hpf, p<0.001) and EREFS-based score (2.0 vs. 4.0, p<0.001) 
were lower than at visits without such treatment. At visits, when patients were treated with 
STC, clinical (31.0 vs. 4.5%, p<0.001), endoscopic (48.8 vs. 17.8%, p<0.001), histological (44.8 
vs. 10.1%, p<0.001), and complete remission (16.1 vs. 1.3%, p<0.001) was more likely to be 
observed compared to visits, when patients were not under STC treatment (Figure 2). If 
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patients had received endoscopic dilation within one year before the visit, the difference 
regarding clinical remission between STC-treated and non-treated patients was less 
pronounced (Supplementary Figure 1). When analyzing remission proportions per patient 
after three follow-up visits (corresponding to the median number of follow-up visits), these 
proportions were higher for patients treated with STC compared to those without 
treatment: 32.2 vs. 6.6% (clinical remission, p<0.001), 45.8 vs. 23.7% (endoscopic remission, 
p=0.007), 49.2 vs. 9.2% (histological remission, p<0.001), and 16.9 vs. 2.6% (complete 
remission, p=0.004, Table 3). 
 At visits under STC, median reported treatment duration was 347 days of past STC 
use (IQR 90-750) corresponding to 677 doses (IQR 280-1413) of 0.25mg of STC. During 144 
visits, patients reported STC treatment duration of one year or longer (median 785 days, IQR 
510-1112, range 370-3780), while during 192 visits, we observed treatment duration of 
shorter than 1 year (median 90 days, IQR 16-194, range 7-364). When examining the number 
of STC doses (in multiples of 0.25mg doses of budesonide or fluticasone, classified into 4 
groups) and the duration of STC treatment (in days, classified into 4 groups) leading to 
follow-up visit, both of these were associated with higher clinical and complete remission 
proportions observed at a given visit (Figure 3). 
Predictive factors for achieving clinical, endoscopic, histological and complete remission in 
patients treated with swallowed topical corticosteroids 
Using first a univariate model for prediction of clinical remission at the time of follow-up 
visit, we identified age at EoE onset (OR 1.02 [1.00-1.03]), longer STC intake (OR 2.68 [1.67-
4.32]), blood eosinophilia (0.37 [0.11-1.19]) and PPI treatment (OR 0.50 [0.27-0.96]) as 
predictive factors with a p-value of <0.10 (Supplementary Table 1). Indeed, at 62/104 of 
visits with clinical remission (59.6%) patients reported long-term use of STC (≥ 1 year), while 
this proportion was significantly lower for visits with no such remission (82/231, 35.5%, 
p<0.001).  However, in a multivariate model only age at disease onset and absence of PPI 
treatment remained significant; Patients without clinical remission despite steroid treatment 
were more likely to be treated with PPI. For prediction of endoscopic and histological 
remission, see Supplementary Table 2 and 3. Longer STC intake and a negative family 
history of EoE were independent positive predictive factors for achieving complete remission 
at a given visit (2.02 [1.12-3.64] and OR 5.06 [1.53-16.75], respectively, Table 2). Indeed, 
during visits of patients in complete remission, higher proportions of long-term STC use and 
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lower proportions of positive family history of EoE were observed when compared to visits 
of patients without such remission (57.4% vs. 40.1%, p=0.02, and 5.7 vs. 32.3%, p=0.004). 
These factors remained significant in a multivariate analysis (Table 2). When cumulative 
doses of STC – instead of treatment duration – were assessed as co-variable, higher doses 
(>600 x 0.25mg) compared to lower STC doses (≤600 x 0.25mg) were an independent 
predictor for achieving complete remission in both the univariate and multivariate 
regression model (corrected for positive family history) to a similar extent of what was seen 
for treatment duration (OR 1.89, p=0.046, and OR 1.90, p=0.049, respectively). 
Per-patient data for maintenance of histological remission 
To further investigate the effect of low-dose STC on maintenance of disease remission, we 
analyzed all patients who achieved histological remission at one of their follow-up visits and 
computed Kaplan Meier curves for time to histological relapse. Patients were stratified into 
STC treatment (defined as under STC treatment at at least one of the following two visits) vs. 
no such STC treatment. 74 patients were identified with achievement of histological 
remission in the follow-up (who were under STC treatment at the time of histological 
remission) and at least 1 second follow-up endoscopy. Time to histological relapse was 
significantly longer in the STC group (1.5 [0.44-2.55] vs. 0.7 years [0.33-1.11], log-rank 
p=0.047, Supplementary Figure 2). 
Clinical activity despite endoscopic and histological remission 
Over the course of 120 visits (120/182, 65.9%, 1.8 years [IQR 0.9-3.5] after enrolment), 
patients presented with EoE-attributed symptoms despite being in endoscopic and 
histological disease remission. When compared to visits of patients in complete remission 
(n=62), visits of patients in endoscopic and histologic but ongoing disease activity (n=120) 
were more likely to be associated with less frequent treatment with STC at the time of 
follow-up visit (62.3 vs. 90%, p<0.001), shorter STC treatment duration (18 vs. 403 days, 
p<0.001) corresponding to a lower number of cumulative STC doses (120 vs. 863, multiples 
of 0.25mg, p<0.001), higher number of strictures (36.5 vs. 6.8%, p<0.001) and endoscopic 
fibrotic features (59.1 vs. 29.1%, p<0.001). No differences between the two groups were 
observed, when gender, atopic history, age at disease onset, and diagnostic delay were 
examined. In a multivariate analysis, lack of STC treatment (OR 7.63 [1.98-29.42]) and 
presence of strictures (OR 12.03 [2.26-63.96]) were the main independent prognostic factors 
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for persisting symptoms despite endoscopic and histological remission during a visit 
(Supplementary Table 4). 
Safety concerns associated with swallowed topical corticosteroid use 
In biopsy samples obtained during 310 visits, for which past STC use was reported (2.0 years 
[IQR 0.7-4.5] after enrolment, 26 visits without histological evaluation), no dysplasia and no 
mucosal atrophy were detected. Histologically and endoscopically confirmed, symptomatic 
esophageal candidiasis warranting antifungal treatment was found at 9/336 of visits under 
STC (2.7%).  
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DISCUSSION 
Swallowed topical corticosteroids have been demonstrated to reliably bring active 
EoE into clinical, endoscopic and histological remission. In contrast, data on long-term 
management and maintenance of remission are sparse. In this study, we comprehensively 
analyzed our Swiss EoE cohort in order to obtain an overview of effectiveness and safety of 
medical maintenance treatment in adult EoE patients. 
The most important finding of our analysis is that STC are more effective than no 
treatment in long-term EoE management. When follow-up visits were performed with 
ongoing medication use the proportion of remission was 16.1%, whereas at visits during 
periods without STC (“drug-holidays”) this proportion was significantly lower (1.3%). This is a 
strong argument that EoE patients – after a successful induction therapy – should be 
considered for maintenance treatment. However, despite this optimistic data, patients 
frequently reported periods without STC use; in fact STC were taken at only 40% of the visits. 
Adherence to treatment seems to be an important issue. However, the periods of 
medication abstinence are comparable with other long-term treatments of chronic 
gastrointestinal diseases, such as inflammatory bowel disease.
11
 With a significant benefit 
from STC over no treatment, but high proportions of patient-initiated medication cessation, 
we advocate for a close monitoring of STC-treated patients including visits more often than 
once a year. Upcoming tools for assessment of histological disease activity such as the 
cytosponge or esophageal string test might facilitate more comprehensive follow-up in the 
future.
12,13
  
Maintenance remission proportions are much lower than those seen after short-term 
induction treatment, leaving considerable room for improvement. Complete remission was 
only seen in 7.6% of 819 analyzed visits. The high proportions of ongoing disease activity, 
whether clinical, endoscopic or histological, shed light on the chronic nature of EoE and 
question the STC doses currently used in long-term management.
14
 Dose-finding trials with 
higher STC doses are definitely needed. Compared to the conducted maintenance trial – 
with remission proportions of 64% (clinical) and 35% (histological) in the adult population – 
clinical and complete remission proportions at visits with patient STC treatment (31 and 
16.1%) were considerably lower in our study.
4
 This might be due to the following reasons: i) 
recall period for symptoms was longer in our study compared to the 1-week recall in the 
maintenance trial, ii) patients in the maintenance trial had closer follow-up visits (every 3 
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months) and more frequent assessment of their symptoms (every 1 week), while our study 
represents real-life conditions, and iii) follow-up was considerably longer in our study. 
Compared to our previously published deep remission study, proportions of complete 
remission (= clinical, endoscopic and histological remission) were however higher (16.1% at 
visits under STC treatment vs. 9.4%), which is most probably due to the less stringent 
histologic definition than that used to define deep remission.
6
  
Despite these low maintenance remission proportions, longer duration of steroid 
treatment and higher cumulative doses were associated with higher proportions of 
complete remission compared to shorter treatment duration and lower doses. In fact, 
treatment for more than one year was an independent positive predictor for achievement of 
complete remission. When four classes of cumulative STC doses and treatment duration 
were compared, significant associations between complete remission, and higher doses and 
longer duration of STC were found. This is consistent with our previous data showing 
increasing, albeit modestly, rates of deep remission over time and lower rates of bolus 
impactions with higher frequency of STC intake.
5,6
 However, in the latter study we reported 
on adherence rather than exact duration and cumulative doses of treatment. Indeed, we 
were able to show associations between treatment duration and doses, and treatment 
outcome in a follow-up maintenance study for the first time. Interestingly, this association 
was only seen between treatment duration and complete remission, and partially clinical 
remission, but not with endoscopic and histological remission. It has yet to be determined if 
this is the result of STC dose accumulation or more due to partial disease regression and 
therefore more treatable disease over time. Either or, treating physicians and some patients 
might anticipate a longer course of low-dose STC maintenance to be effective. It remains 
unclear, why a small subset of patients achieved endoscopic and histological disease 
remission without STC treatment. We cannot rule out that some patients adhered to self-
initiated dietary restrictions or under-reported STC use. Based on our previous study, 
ongoing disease remission without any treatment is very unlikely.
6
 
It is well established that long-term use of corticosteroids poses risk for side-effects. 
For instance the administration of topical corticosteroids to the skin results in epithelial 
atrophy and disruption of epithelial integrity.
7,8
 Since the skin and the esophagus share many 
similarities regarding their histo-morphological structure, this potential side-effect requires 
careful exploration, because it may further facilitate antigen and fungal entry. In EoE, STC in 
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the applied dose of 0.25mg b.i.d. appear to be safe and well-tolerated. Esophageal candida 
infections occur in a negligible proportion. In addition, our finding that no single case of 
mucosal atrophy, dysplasia was detected is reassuring. A dose of 0.25mg b.i.d. – even in the 
long-term – is not harmful to the esophageal epithelial layer. This is consistent with our 
previous study,
6
 but the biopsy number examined for the purposes of this study is 
considerably higher.  
Since PPI responsiveness was an exclusion criteria, our study does not account for 
PPI-responsive EoE (PPI-REE). However, this reflected the state of the art, when the 
treatment concept was launched. PPI-REE and PPI as treatment for EoE have been included 
in the guidelines only very recently.
15
 A clear limitation of this study is that the applied dose 
of STC was most probably too low to achieve adequate drug levels in the esophageal 
mucosa. Thus, the high proportion of refractory cases most likely resulted from inadequate 
dosing. This is supported by our finding that higher cumulative doses of STC are associated 
with a higher probability of disease remission. This apparently suboptimal dose was chosen 
as side-effects were an important concern when determining the therapeutic dose to be 
used. Furthermore, 0.25mg b.i.d had shown a benefit over placebo in the only maintenance 
trial conducted in adults so far.
4
 Since our concept with low-dose STC is rigorously applied in 
our EoE cohort, a comparison to patients with higher maintenance doses was not possible, 
but would be of particular interest in the future. Further limitations were the use of a non-
validated symptom score, the reliance on patient-reported STC intake, and the considerable 
amount of missing data, which could have biased our results. Since almost all patients were 
treated with fluticasone, stratification by STC compound was not feasible. 
In conclusion, EoE patients benefit from a long-term treatment with STC. This 
regimen has an excellent safety profile and the potential to alter the course of the disease. 
Of note, our data show that longer treatment and higher cumulative doses of STC are 
associated with higher proportions of disease remission. Based on this data, we advocate for 
indefinite long-term EoE treatment with STC. Given that patients rarely achieved complete 
remission with the STC doses used for the purposes of their clinical care, prospective long-
term trials comparing different doses are needed in the future.  
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LEGENDS 
Table 1: Patient, disease characteristics at baseline, during follow-up. 
Table 2: Logistic regression model for predicting complete remission in all patients and STC-
treated patients. 
Table 3: Patient follow-up and per-patient remission data after the median 
number of follow-up visits (=3 visits). *for 3 patients STC treatment could not 
be verified. 
Figure 1: Flow-chart of included, excluded patients 
Figure 2: Clinical, endoscopic, histological, and complete remission at the time of all follow-
up visits, and stratified into visits, during which STC treatment or no treatment was 
undertaken. Darker shade represents remission. 
Figure 3: Clinical and complete remission in patients stratified into groups based on STC 
treatment duration (in days [d]) and cumulative number of doses (in multiples of 0.25mg). 
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Patient demographics and disease characteristics at baseline Frequency (n=229 patients) 
Males 175 (76.4%) 
Age at EoE diagnosis (mean, SD) (years) 39, 15 
Diagnostic delay (median, IQR, range) (years) 6, 2 - 13, 0 - 40 
Family history for EoE 
- proven 
- suspected 
 
27 (11.8%) 
16 (7.0%) 
Symptoms leading to EoE diagnosis 
- Dysphagia 
- Chest pain 
- Reflux 
- Abdominal pain 
 
216 (94.3%) 
81 (35.4%)  
16 (7.0%) 
4 (1.7%) 
Concomitant atopic diseases (ever reported) 144 (62.9%) 
Concomitant gastroesophageal reflux disease at baseline 27 (11.8 %) 
Endoscopic disease activity  
Strictures 81 (35.4 %)  
Corrugated rings 145 (63.3 %)  
White exudates 115 (50.2 %)  
Edema 164 (71.6%)  
Furrows 146 (63.8 %)  
Histological disease activity  
Peak eosinophil count per hpf, median (IQR) 37, 22-65 
Active histological disease  217 (94.8%) 
Subepithelial fibrosis 
- Mild to moderate 
- Severe 
 
67 (29.3 %)  
15 (6.6 %)  
Disease characteristics during follow-up Frequency (n=819 visits) 
Follow-up, median (IQR) (years) 5 (3-7) 
Number of follow-up visits per patient, median (IQR) 3 (2-5) 
Endoscopic dilation at the time of follow-up 125 (15.3%) 
Prior endoscopic dilation (within 1 year) at the time of follow-up 47 (5.7%) 
Clinical characteristics 
Presence of EoE-related symptoms 684 (83.5%) 
PPI treatment 163 (19.9%) 
STC treatment during visits 336 (41.0%) 
Endoscopic findings 
Endoscopic inflammatory signs 539 (65.8%) 
Endoscopic fibrotic features 392 (47.9%) 
Strictures  245 (29.9%) 
EREFS-based score, median (IQR) 3 (1-4) 
Histologic findings 
Peak eosinophil count per hpf, median (IQR) 25 (1.0-65.0) 
Peak count of ≥ 15 eosinophils/hpf 539 (65.8%) 
Subepithelial fibrosis 
- mild to moderate 
Assessed during 277 visits 
200 (72.2%) 
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- severe 58 (20.9%) 
Dysplasia 0 (0.0%) 
Table 1: Patient and disease characteristics at baseline and during follow-up. 
Abbreviations: EREFS, endoscopic reference score; hpf, high-power field; IQR, interquartile 
range; PPI, proton-pump inhibitor; SD, standard deviation 
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Prediction of complete remission in all patients  
 Univariate model  Multivariate model  
Candidate risk factor OR, 95% CI P-value  OR, 95% CI P-Value 
Gender 
- Male 
- Female 
 
ref. 
0.870 (0.469-1.614) 
 
 
0.660 
   
Age at onset 1.002 (0.989-1.016) 0.746    
Diagnostic delay 0.989 (0.957-1.023) 0.528    
Blood eosinophilia 
- Absent 
- Present 
 
ref. 
0.497 (0.129-1.913) 
 
 
0.309 
   
Elevated IgE levels 
- Absent 
- Present 
 
ref. 
1.020 (0.291-3.575) 
 
 
0.975 
   
Therapy with STC 
- No 
- Yes 
 
ref. 
14.745 (6.262-
34.717) 
 
 
<0.001 
  
ref. 
16.983 (6.694-43.090) 
 
 
<0.001 
PPI therapy 
- No 
- Yes 
 
ref. 
0.954 (0.495-1.838) 
 
 
0.887 
   
Family history 
- Positive 
- Negative 
 
ref. 
4.060 (1.451-11.365) 
 
 
0.008 
  
ref. 
4.021 (1.410-11.466) 
 
 
0.009 
Allergic conditions  
- No 
- Yes 
 
ref. 
0.762 (0.438-1.324) 
 
 
0.335 
   
Prediction of complete remission in STC treated patients 
 Univariate model  Multivariate model  
Candidate risk factor OR, 95% CI P-value  OR, 95% CI P-Value 
Gender 
- Male 
- Female 
 
ref. 
1.080 (0.545-2.139) 
 
 
0.825 
  
Age at onset 1.008 (0.989-1.028) 0.412   
Diagnostic delay 0.997 (0.964-1.032) 0.866   
Blood eosinophilia 
- Absent 
- Present 
 
ref. 
0.918 (0.221-3.818) 
 
 
0.907 
  
Elevated IgE levels 
- Absent 
- Present 
 
ref. 
0.764 (0.199-2.940) 
 
 
0.696 
  
Long duration of STC 
use 
- No (<1 year) 
- Yes (≥1 
year) 
 
 
ref. 
2.016 (1.118-3.635) 
 
 
 
0.020 
 
 
ref. 
1.976 (1.082-3.610) 
 
 
 
0.027 
PPI therapy 
- No 
- Yes 
 
ref. 
0.867 (0.411-1.828) 
 
 
0.708 
  
Family history 
- Positive 
- Negative 
 
ref. 
5.055 (1.525-16.753) 
 
 
0.008 
 
ref. 
5.103 (1.534-16.976) 
 
 
0.008 
Allergic conditions  
- No 
- Yes 
 
ref. 
0.805 (0.432-1.500) 
 
 
0.495 
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Table 2: Logistic regression model for predicting complete remission in all 
patients and STC-treated patients at the time of follow-up. Abbreviations: PPI, 
proton-pump inhibitor; STC, swallowed topical corticosteroids. 
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Follow-up of patients Frequency (n=229) 
Follow-up visits 
- 1 follow-up visit 
- 2 follow-up visits 
- 3 follow-up visits 
- 4 follow-up visits 
- 5 follow-up visits 
- >5 follow-up visits 
 
34 (14.8%) 
57 (24.9%) 
39 (17.0%) 
39 (17.0%) 
28 (12.2%) 
32 (14.0%) 
Remission rates for patients at Visit 3  n=138 
Patients in clinical remission 24 (17.4%) 
Patients in endoscopic remission 45 (32.6%) 
Patients in histological remission 36 (26.1%) 
Patients in complete remission 12 (8.7%) 
Remission rates for patients without STC treatment at Visit 
3 
n=76 
Patients in clinical remission 5 (6.6%) 
Patients in endoscopic remission 18 (23.7%) 
Patients in histological remission 7 (9.2%) 
Patients in complete remission  2 (2.6%) 
Remission rates for patients under treatment with STC at 
Visit 3 
n=59* 
Patients in clinical remission 19 (32.2%) 
Patients in endoscopic remission 27 (45.8%) 
Patients in histological remission 29 (49.2%) 
Patients in complete remission  10 (16.9%) 
Table 3: Patient follow-up and per-patient remission data after the median number of 
follow-up visits (=3 follow-up visits). *For 3 patients STC treatment at visit 3 could not be 
verified. STC, swallowed topical corticosteroids 
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31.1	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92.4	  
4.5	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SUPPLEMENTARY TABLES 
 Univariate model  Multivariate model  
Candidate risk factor OR, 95% CI P-value  OR, 95% CI P-Value 
Gender 
- Male 
- Female 
 
ref. 
1.074 (0.617-1.870) 
 
 
0.800 
  
 
 
 
Age at onset 1.018 (1.002-1.034 0.026  1.054 (1.012-1.098) 0.012 
Diagnostic delay 0.981 (0.953-1.009) 0.185    
Blood eosinophilia 
- Absent 
- Present 
 
ref. 
0.366 (0.113-1.190) 
 
 
0.095 
  
ref 
0.671 (0.186-2.423) 
 
 
0.543 
Elevated IgE levels 
- Absent 
- Present 
 
ref. 
1.306 (0.471-3.622) 
 
 
0.608 
   
Long duration of STC 
use 
- No (<1 year) 
- Yes (≥1 year) 
 
 
ref. 
2.682 (1.667-4.315) 
 
 
 
<0.001 
  
 
ref. 
0.733 (0.213-2.519) 
 
 
 
0.622 
PPI therapy 
- No 
- Yes 
 
ref. 
0.503 (0.265-0.955) 
 
 
0.036 
  
ref. 
0.083 (0.009-0.755) 
 
 
0.027 
Family history 
- Negative 
- Positive 
 
ref. 
0.594 (0.316-1.115) 
 
 
0.105 
  
 
 
 
 
Prior dilation (within 1 
year) 
- No 
- Yes 
 
 
ref. 
1.283 (0.520-3.161) 
 
 
 
0.589 
   
Allergic conditions  
- No 
- Yes 
 
ref. 
1.061 (0.640-1.759) 
 
 
0.818 
   
Supplementary Table 1: Logistic regression model for predicting clinical 
remission in patients treated with swallowed topical steroids at the time of 
follow-up visit. PPI, proton-pump inhibitor; STC, swallowed topical 
corticosteroids.  
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 Univariate model  Multivariate model  
Candidate risk factor OR, 95% CI P-value  OR, 95% CI P-Value 
Gender 
- Male 
- Female 
 
ref. 
0.727 (0.432-1.222) 
 
 
0.229 
  
 
 
 
Age at onset 1.007 (0.992-1.022) 0.351    
Diagnostic delay 1.003 (0.978-1.029) 0.812    
Blood eosinophilia 
- Absent 
- Present 
 
ref. 
0.219 (0.080-0.604) 
 
 
0.003 
  
ref. 
0.246 (0.087-0.696) 
 
 
0.008 
Elevated IgE levels 
- Absent 
- Present 
 
ref. 
0.731 (0.305-1.755) 
 
 
0.484 
   
Long duration of STC 
use 
- No (<1 year) 
- Yes (≥1 year) 
 
 
ref. 
1.172 (0.758-1.814) 
 
 
 
0.475 
  
 
 
 
 
PPI therapy 
- No 
- Yes 
 
ref. 
1.178 (0.693-2.004) 
 
 
0.545 
   
Family history 
- Negative 
- Positive 
 
ref. 
0.651 (0.375-1.132) 
 
 
0.129 
  
 
 
 
 
Allergic conditions  
- No 
- Yes 
 
ref. 
0.570 (0.353-0.918) 
 
 
0.021 
  
ref. 
0.547 (0.218-1.375) 
 
 
0.200 
Supplementary Table 2: Logistic regression model for predicting endoscopic 
remission in patients treated with swallowed topical steroids at the time of 
follow-up visit. PPI, proton-pump inhibitor; STC, swallowed topical 
corticosteroids.  
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 Univariate model  Multivariate model  
Candidate risk factor OR, 95% CI P-value  OR, 95% CI P-Value 
Gender 
- Male 
- Female 
 
ref. 
0.836 (0.488-1.433) 
 
 
0.515 
  
 
 
 
Age at onset 0.997 (0.982-1.012) 0.683    
Diagnostic delay 1.009 (0.983-1.035) 0.518    
Blood eosinophilia 
- Absent 
- Present 
 
ref. 
0.266 (0.096-0.734) 
 
 
0.011 
  
ref 
0.265 (0.085-0.828) 
 
 
0.022 
Elevated IgE levels 
- Absent 
- Present 
 
ref. 
0.559 (0.230-1.358) 
 
 
0.199 
   
Long duration of STC 
use 
- No (<1 year) 
- Yes (≥1 year) 
 
 
ref. 
0.859 (0.547-1.348) 
 
 
 
0.509 
  
 
 
 
 
 
 
 
PPI therapy 
- No 
- Yes 
 
ref. 
1.365 (0.789-1.362) 
 
 
0.266 
   
Family history 
- Negative 
- Positive 
 
ref. 
0.540 (0.302-0.965) 
 
 
0.038 
  
ref. 
0.328 (0.083-1.293) 
 
 
0.111 
Allergic conditions  
- No 
- Yes 
 
ref. 
0.534 (0.327-0.870) 
 
 
0.012 
  
ref. 
1.510 (0.552-4.129) 
 
 
0.422 
Supplementary Table 3: Logistic regression model for predicting histological 
remission in patients treated with swallowed topical steroids at the time of 
follow-up visit. PPI, proton-pump inhibitor; STC, swallowed topical 
corticosteroids.  
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 Univariate model  Multivariate model  
Candidate risk factor OR, 95% CI P-value  OR, 95% CI P-Value 
Gender 
- Male 
- Female 
 
ref. 
1.043 (0.503-2.166) 
 
 
0.909 
   
Age at onset 0.997 (0.978-1.017) 0.787    
Diagnostic delay 1.023 (0.985-1.063) 0.230    
Blood eosinophilia 
- Absent 
- Present 
 
ref. 
0.513 (0.100-2.633) 
 
 
0.424 
   
Elevated IgE levels 
- Absent 
- Present 
 
ref. 
0.615 (0.146-2.602) 
 
 
0.509 
   
Strictures 
- Absent 
- Present 
 
ref. 
7.911 (2.677-23.380) 
 
 
<0.001 
  
ref. 
12.033 (2.264-
63.955) 
 
 
0.004 
Endoscopic fibrosis 
- Absent 
- Present 
 
ref. 
3.521 (1.713-7.237) 
 
 
0.001 
  
ref. 
1.437 (0.542-3.810) 
 
 
0.466 
Therapy with STC 
- Yes 
- No 
 
ref. 
5.451 (2.162-13.740) 
 
 
<0.001 
  
ref. 
7.631 (1.980-
29.418) 
 
 
0.003 
PPI therapy 
- No 
- Yes 
 
ref. 
1.314 (0.614-2.814) 
 
 
0.482 
   
Family history 
- Negative 
- Positive 
 
ref. 
3.128 (1.021-9.579) 
 
 
0.046 
  
ref. 
7.817 (1.580-
38.673) 
 
 
0.012 
Prior dilation (within 
1 year) 
- No 
- Yes 
 
 
ref. 
1.188 (0.296-4.770) 
 
 
 
0.808 
   
Allergic conditions  
- No 
- Yes 
 
ref. 
0.819 (0.427-1.571) 
 
 
0.548 
   
Supplementary Table 4: Logistic regression model for predicting ongoing 
clinical activity despite endoscopic and histological remission. PPI, proton-
pump inhibitor; STC, swallowed topical corticosteroids. 
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SUPPLEMENTARY METHODS 
Inclusion criteria for the Swiss EoE database 
Briefly, patients with active disease based on presence of typical EoE-associated symptoms, 
endoscopic features, and esophageal eosinophilia, defined as a peak count of ≥ 15 
eosinophils (eos) per high power field (hpf) were included. Patients were excluded, if other 
diseases associated with esophageal eosinophilia were present. Underlying gastro-
esophageal reflux disease (GERD) was excluded based on any one of the following: lack of 
typical symptoms (heartburn and acid regurgitation), absence of hiatal hernia and signs of 
reflux esophagitis, non-response to PPI trial, or a positive 24-hour pH monitoring study 
(optional). Patients with persistent dysphagia and eosinophil inflammation, whose 
symptoms and signs of GERD resolved following PPI treatment, were considered to have EoE 
and concomitant GERD and were not excluded from the SEED. 
Therapeutic concept of maintenance treatment with STC 
Based on our clinical experience and the findings of a maintenance treatment study, the 
following long-term concept was developed, and patients of the Swiss EoE Clinic have been 
treated according to the following principles: 
- Clinically and histologically active EoE was considered to be a clear indication for 
treatment; 
- STC (fluticasone or budesonide) was used as first line treatment for induction and 
maintenance of EoE remission; 
- The following treatment schedule was used: Induction treatment with fluticasone or 
budesonide at the dose of 1.0 mg b.i.d. (2.0 mg per day) was administered until clinical 
response (defined as 50-70% reduction from baseline symptoms on a 10-point scale [non-
validated symptom assessment]) was achieved (usually following 2-4 weeks of 
treatment); a maintenance treatment with fluticasone or budesonide at the dose of 0.25 
mg b.i.d. (=0.5 mg per day) followed; 
- Clinical, endoscopic and histological examination was performed once a year. During each 
visit, the patients were asked about the presence and the severity of EoE- and GERD- 
related symptoms, their eating habits, and their treatment regimen (cumulative dose and 
duration of treatment).  Endoscopic findings were described in detail in a written report 
and documented with pictures. Four biopsies were taken from each the proximal and 
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distal esophagus (total of eight biopsies). As previously described, ‘distal’ was defined as 
the section of the esophagus 5 cm above the gastro-esophageal junction, whereas 
‘proximal’ was defined as the section spanning the top half of the esophagus. All biopsies 
were examined by an EoE reference pathologist (CB) or pathologist under his supervision. 
For the histologic examination, 4-µm sections were cut from the paraffin blocks. They 
were stained with Hematoxylin & Eosin and van Gieson stain. In all cases, a standard 
pathology microscope (Zeiss Axiophot, Plan-Neofluar 40, ocular magnification 10 ×, area 
of microscopic field 0.3072 mm
2
) was used. At least 10 sections of each esophageal 
biopsy sample were examined, and the peak eosinophil count was reported; 
- As long as a disease activity was documented clinically, endoscopically, and/or 
histologically, the treatment with STC was continued for another year; 
- In case of deteriorating clinical, endoscopic, and/or histological disease activity, 
patients underwent a second induction treatment for a period of 2-4 weeks. 
Type of STC and drug formulations 
At our Swiss EoE Clinic, two STC formulations are prescribed for long-term maintenance 
treatment: 1) fluticasone powder from a metered-dose inhaler for asthma (one blister 
containing 0.25mg of fluticasone applied orally and swallowed twice a day); and 2) 
budesonide respules dissolved in syrup with a sucrose concentration of 64% (1ml syrup = 
0.03mg budesonide, swallowed at a dose of 0.25mg b.i.d.). For practical reasons – syrup 
needs to be individually prepared by a pharmacy, while fluticasone inhalers are readily 
available – fluticasone is the treatment of choice for most of the patients. 
Additional statistical analyses 
For all statistical analyses, IBM SPSS software (version 22.0.0, 2013 SPSS Science, Chicago, IL) 
was used. Data distribution was analyzed using Normal-QQ-Plots. Results of quantitative 
data are presented as either mean ± standard deviation (SD, for normally distributed data) 
or median plus interquartile range (IQR) in case of non-normal distribution. Categorical data 
are summarized as the percentage of the group total. Differences in quantitative data 
distributions between two groups were assessed using the unpaired Student’s t-test (for 
continuous variables with normal distribution) and the Mann-Whitney-Wilcoxon test (for 
non-parametric data or continuous, but non-normally distributed data). Comparison 
between categorical data was performed using χ
2 
test. Multivariate logistic regression was 
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performed by first taking into account all covariates with univariate p-value of < 0.1, 
removing insignificant covariates, and then adding remaining covariates one by one, 
checking the model for significance and consistency. For prediction of remission (clinical, 
endoscopic, histological and complete remission as dependent variables), the following 
factors were analyzed: gender (coded as male or female), age at disease onset, diagnostic 
delay, blood eosinophilia (coded as present [>350 eos/μL] or absent [≤350 eos/μL]), elevated 
IgE levels (coded as present [>100 kU/L] or absent [≤100 kU/L]), treatment with STC (coded 
as yes or no) or duration of STC treatment (coded as long [≥1 year] or short [<1 year]), 
treatment with PPI (coded as yes or no), family history of EoE (coded as positive or negative), 
and presence of allergic conditions (coded as yes or no). To evaluate the factors, that might 
be associated with ongoing clinical activity despite endoscopic, histological remission 
(ongoing symptoms as dependent variable), we additionally analyzed the following co-
variables: strictures (coded as present or absent), endoscopic fibrotic signs (coded as present 
or absent), and prior endoscopic dilation (within one year before the examined visit, coded 
as yes or no). The linear-by-linear association test for trend was used to assess the 
association between duration of STC treatment (< 100 days, 100 - < 200 days, 200 - 300 days, 
and > 300 days) and frequency of disease remission, and to the assess association between 
cumulative doses of steroids (< 200, 200 - < 400, 400 - 600, > 600 × 0.25 mg) and disease 
remission. For the purpose of this study, a p-value of < 0.05 was considered statistically 
significant. 
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Editor`s notes: MAINTENANCE TREATMENT OF EOSINOPHILIC ESOPHAGITIS WITH 
SWALLOWED TOPICAL STEROIDS ALTERS DISEASE COURSE OVER A 5-YEAR FOLLOW-UP 
PERIOD IN ADULT PATIENTS 
 
Background: Data on long-term management of eosinophilic esophagitis (EoE) with 
swallowed topical corticosteroids are limited. 
 
Findings: Swallowed topical corticosteroids are more effective than no treatment in the 
long-term management of EoE. Maintenance remission proportions are lower than those 
seen after short-term induction treatment. Nonetheless, longer duration of steroid 
treatment and higher cumulative doses are associated with higher proportions of complete 
remission compared to shorter duration and lower doses. An applied dose of 0.25mg b.i.d is 
safe and well-tolerated. 
 
Implications for patient care: Indefinite long-term EoE treatment with swallowed topical 
corticosteroids should be considered. Given that patients rarely achieve complete remission 
with the steroid doses used for the purposes of their clinical care, prospective long-term 
trials comparing different doses are needed in the future. 
 
 
